利妥昔单抗治疗多发性硬化症和视神经脊髓炎患者的安全性和临床结果:来自国家在线注册(GRAID)的经验

IF 5.2 3区医学 Q1 NEUROSCIENCES

Journal of Neuroimmune Pharmacology Pub Date : 2015-11-20 DOI:10.1007/s11481-015-9646-5

P. Rommer, T. Dörner, K. Freivogel, J. Haas, B. Kieseier, T. Kümpfel, F. Paul, F. Proft, H. Schulze-Koops, E. Schmidt, H. Wiendl, U. Ziemann, U. Zettl

引用次数: 35

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Neuroimmune Pharmacology 医学-神经科学

CiteScore

13.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The aims of the Journal of Neuroimmune Pharmacology are to promote the dissemination, interest, and exchange of new and important discoveries for the pharmacology and immunology of the nervous system. The aims parallel that of the Society on NeuroImmune Pharmacology by increasing the fundamental understanding of neurologic and neuropsychiatric disorders affected by the immune system or vice versa and towards pharmacologic measures that lead, either to a better understanding of disease mechanisms, or by improving disease outcomes. The scope of JNIP includes all primary works and reviews into the etiology, prevention, and treatment of neuroimmune and nervous system diseases affected by disordered immunity. Original studies serving to define neuroimmune modulation of environmental or endogenous cues such as toxins and drugs of abuse, hormones, and cytokines are welcome. JNIP will serve as a reliable source of interdisciplinary information bridging the fields of pharmacology, immunology, and neuroscience.